Menu
Recruiting NCT06072430

A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)

Phase III Interventional Septic Shock Sepsis Hypovolemia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: VBI-S.
Who it may be relevant to
Registry conditions: Septic Shock, Sepsis, Hypovolemia. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock

Overview

This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.

Detailed description

PURPOSE OF THE STUDY This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.

STUDY TREATMENT Sepsis is a serious condition resulting from the presence of harmful microorganisms in the blood or other tissues and the body's response to their presence, leading to the malfunctioning of various organs. When hypotension due to sepsis cannot be reversed with the infusion of fluids the patient is in a state of septic shock. Septic shock is therefore an acute medical emergency and delayed therapy can lead to organ injury. VBI-S is intended to raise blood pressure in patients with septic shock.

Randomization and blinding: This is a randomized, controlled, open-label study and blinding is not applicable to this study.

Data Safety Monitoring Board: A Data Safety Monitoring Board (DSMB) will review the study data.

Interventions

  • Drug VBI-S
    VBI-S is made of small particles of specific lipids called micelles and liposomes for the treatment of hypotension.

Primary outcome measures

  • Elevation in Average Mean Arterial Pressure [Time frame: 12 months]
Secondary outcome measures (8)
  • Dose of Pressor Drugs [Time frame: 12 months]
  • Sequential Organ Failure Assessment (SOFA) Score [Time frame: 12 months]
  • Ratio of Arterial Partial Pressure of Oxygen/Fraction of Inspired Oxygen [Time frame: 12 months]
  • Arterial Oxygen Saturation [Time frame: 12 months]
  • Partial Pressure of Oxygen [Time frame: 12 months]
  • Serum Procalcitonin [Time frame: 12 months]
  • Serum Creatinine [Time frame: 12 months]
  • Post-treatment Survival [Time frame: 12 months]

Eligibility criteria

Inclusion criteria

  • Male or female at least 18 years of age.
  • Evidence of bacterial infection demonstrated by positive blood culture and/or a known source of infection and/or an elevated procalcitonin of ≥ 2 ng/ml.
  • Patient has a mean blood pressure < 65 mmHg that is unresponsive to fluids currently available on the market.
  • Sequential Organ Failure Assessment (SOFA) score ≥ 5
  • Sepsis diagnosis: The presence of infection which can be proven or suspected by 2 or more of the following criteria:
  • Lactate > 2 mmol/L
  • Fever > 38.3°C, or 101°F
  • Hypothermia < 36°C core temperature (<96.8°F)
  • Heart rate > 90
  • Tachypnea (respiratory rate ≥ 20/min)
  • White blood cell count >12,000 or less than 4,000, or with >10% "bands" (immature forms)
  • Elevated procalcitonin in serum (≥ 2ng/ml)
  • Arterial hypoxemia (PaO2/FiO2 < 300)
  • Creatinine increase > 0.5 mg/dL since hospital admission
  • INR > 1.5 or aPTT > 60 seconds
  • Documented dysregulated host response to an infection as indicated by an increase in SOFA score by ≥ 2 points after an infection per the SEPSIS 3 guideline.
  • Receiving vasopressors to maintain the target MAP of 65 mmHg.

Exclusion criteria

  • Patients with a ventricular assist device
  • Acute coronary syndrome
  • Pregnant
  • Acute bronchospasm
  • Acute Mesenteric ischemia
  • Emergency major surgery
  • Diagnosis of acute Hepatitis B or C.
  • Hematologic or coagulation disorders including thrombocytopenia (platelet count <50,000) and associated with hemodynamically significant active bleeding that causes a decrease in blood pressure.
  • White blood cell count of < 1000 mm3
  • Current participation or participation in another experimental or device study within the last 30 days before the start of this study. Patient may be included if on other drugs are for COVID-19.
  • Patients with a known allergy to soybeans or eggs
  • Patient is hypervolemic with assessment by physician or physician extender ultrasound 12 hours before infusion of VBI-S if hypervolemia is suspected.
  • Patient expected to expire within 12 hours.
  • Patients with disturbances in normal fat metabolism such as pathologic hyperlipemia, lipid nephrosis, or acute pancreatitis with hyperlipidemia.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 6 centers
  • Dignity Health Chandler Regional Medical Center — Chandler
  • Memorial Health University Medical Center — Savannah
  • University Health — Kansas City
  • Bryan Medical Center — Lincoln
  • Novant Healthcare — Winston-Salem
  • Oregon Health & Science University (OHSU) — Portland

Identifiers

NCT: NCT06072430 · VBI-S-02

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗